Sepragen.com

Home | Contact Us 


Online Catalog


View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at sales@sepragen.com.



How Can We Help You?
Click here to contact us!

 



Sepragen wins Phase 1 STTR award from National Science Foundation for using its Express bioreactor technology to develop a low cost process for recombinant Heparin

July 15, 2013, Hayward, CA ... Sepragen Corporation announces the award of a Phase 1 STTR by NSF for a collaborative project application jointly submitted by Sepragen and its academic partner SUNY, Albany.

The award of $250,000 is for the two parties to work on using Sepragen’s unique wicking matrix high density bioreactor for growing the Heparin expressing cell line. Heparin is an anticoagulant protein widely used in surgery with a $6Bn market. It is currently extracted from pig intestines and is manufactured mostly in China. It was notoriously in the news a few years ago when contaminated Heparin resulted in several deaths. The quest to make a genetically engineered Heparin via mammalian cell culture, manufactured in a safe and controlled environment has thus of late certainly become a desirable societal goal. Equally important is the ability to make this protein cost effectively.

This project contemplates using Sepragen’s Express wicking bioreactor (which has been previously demonstrated to result in 30X the cell density or productivity of conventional cell culture) to grow Heparin producing cells to high densities and have them continuously express Heparin or Heparin analogs whih would then be suitably purified. If successful, the bioreactor could very well enable high density Heparin secreting cells to be grown in a small footprint plant thereby reducing both capital and operating costs dramatically. The two parties in that case would pursue further optimization and scale up studies jointly via and would anticipate for a much bigger a Phase 2 award STTR grant in 2014.

Return to News and Events main page



The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.


Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2017 Sepragen Corporation. All rights reserved. (510) 475-0650